There is an increasing need for new diagnostic tests in many disease areas, including those associated with an increasingly ageing population. Identifying these diseases quickly and efficiently can be vital in maintaining a patient's quality of life. New drug modalities are evolving alongside innovative diagnostics, which is leading to improved patient management and monitoring of treatment efficacy.
The core focus of our business continues to be on innovation and the development of new markers that will increase testing and improve patient care.
We are continually striving to develop improved methods to diagnose disease, employing both in-house expertise and our links with external centres of excellence. More than 50 scientists are employed in this capacity in our research centres in Norway and Scotland.
Since our inception, we have successfully implemented our strategy of growth through the development and marketing of novel diagnostic tests in areas of clinical need. Key products illustrating this include:
In line with this continuing strategy, we are working on markers in a number of different clinical areas including our exciting test for Heparin Binding Protein - a new marker for diagnosis and monitoring of severe sepsis.
We welcome discussion with organisations or individuals wishing to accelerate development, clinical evaluation and commercialisation of any novel markers and potential clinical utility.
A pioneering organisation focused on the development and manufacturing of important and innovative in vitro diagnostic tests for use in clinical laboratories and at the point of care.
As a general marker of overall health status, few tests carry greater predictive weight than Homocysteine. The amount of Homocysteine in your blood is one of the best independent indicators of how healthy you are.